BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT02398929
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT02398929
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Hong Kong SAR China
- Registry status
- Completed
Technical summary
Registry record NCT02398929. Allocation not applicable; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2021-01-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)
- Acronym
- BRAVE
- Condition
- Hypertension
- Intervention (Drug)
- Bisoprolol 2.5 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Chinese University of Hong Kong
Record details
- Record id
cardio:ct-nct02398929- Content hash
de96f55f955bb4140c7103c1f56dca8e7d4c279e3f5cc150e15b4a2aa290f1b2